176 related articles for article (PubMed ID: 38741565)
61. Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they?
de Bortoli N; Martinucci I; Savarino E; Bellini M; Bredenoord AJ; Franchi R; Bertani L; Furnari M; Savarino V; Blandizzi C; Marchi S
Neurogastroenterol Motil; 2014 Jan; 26(1):28-35. PubMed ID: 23992024
[TBL] [Abstract][Full Text] [Related]
62. Efficacy of transoral incisionless fundoplication (TIF) for the treatment of GERD: a systematic review with meta-analysis.
Huang X; Chen S; Zhao H; Zeng X; Lian J; Tseng Y; Chen J
Surg Endosc; 2017 Mar; 31(3):1032-1044. PubMed ID: 27495332
[TBL] [Abstract][Full Text] [Related]
63. Tegoprazan to treat gastroesophageal reflux disease.
Mermelstein J; Mermelstein AC; Chait MM
Drugs Today (Barc); 2020 Nov; 56(11):715-721. PubMed ID: 33332479
[TBL] [Abstract][Full Text] [Related]
64. Systematic review: Patterns of proton pump inhibitor use and adherence in gastroesophageal reflux disease.
Hungin AP; Hill C; Molloy-Bland M; Raghunath A
Clin Gastroenterol Hepatol; 2012 Feb; 10(2):109-16. PubMed ID: 21782770
[TBL] [Abstract][Full Text] [Related]
65. Laparoscopic magnetic sphincter augmentation versus double-dose proton pump inhibitors for management of moderate-to-severe regurgitation in GERD: a randomized controlled trial.
Bell R; Lipham J; Louie B; Williams V; Luketich J; Hill M; Richards W; Dunst C; Lister D; McDowell-Jacobs L; Reardon P; Woods K; Gould J; Buckley FP; Kothari S; Khaitan L; Smith CD; Park A; Smith C; Jacobsen G; Abbas G; Katz P
Gastrointest Endosc; 2019 Jan; 89(1):14-22.e1. PubMed ID: 30031018
[TBL] [Abstract][Full Text] [Related]
66. ARE THE PERSISTENT SYMPTOMS TO PROTON PUMP INHIBITOR THERAPY DUE TO REFRACTORY GASTROESOPHAGEAL REFLUX DISEASE OR TO OTHER DISORDERS?
Azzam RS
Arq Gastroenterol; 2018 Nov; 55Suppl 1(Suppl 1):85-91. PubMed ID: 30304291
[TBL] [Abstract][Full Text] [Related]
67. Efficacy and safety of traditional Chinese herbal formula combined with western medicine for gastroesophageal reflux disease: A protocol for systematic review and meta-analysis.
Lin W; Huang G; Liu X; Lin H; Zhou H; Feng C; Wang T; Liang R
Medicine (Baltimore); 2020 Oct; 99(41):e22454. PubMed ID: 33031277
[TBL] [Abstract][Full Text] [Related]
68. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.
van Pinxteren B; Numans ME; Bonis PA; Lau J
Cochrane Database Syst Rev; 2006 Jul; (3):CD002095. PubMed ID: 16855986
[TBL] [Abstract][Full Text] [Related]
69. The Prevalence and Clinical Features of Non-responsive Gastroesophageal Reflux Disease to Practical Proton Pump Inhibitor Dose in Korea: A Multicenter Study.
Park HJ; Park SH; Shim KN; Kim YS; Kim HJ; Han JP; Kim YS; Bang BW; Kim GH; Baik GH; Kim HH; Park SY; Kim SS
Korean J Gastroenterol; 2016 Jul; 68(1):16-22. PubMed ID: 27443619
[TBL] [Abstract][Full Text] [Related]
70. IW-3718 Reduces Heartburn Severity in Patients With Refractory Gastroesophageal Reflux Disease in a Randomized Trial.
Vaezi MF; Fass R; Vakil N; Reasner DS; Mittleman RS; Hall M; Shao JZ; Chen Y; Lane L; Gates AM; Currie MG
Gastroenterology; 2020 Jun; 158(8):2093-2103. PubMed ID: 32092310
[TBL] [Abstract][Full Text] [Related]
71. Maintenance treatment of mild gastroesophageal reflux disease with proton pump inhibitors taken on-demand: a meta-analysis.
Jiang YX; Chen Y; Kong X; Tong YL; Xu SC
Hepatogastroenterology; 2013; 60(125):1077-82. PubMed ID: 23803372
[TBL] [Abstract][Full Text] [Related]
72. Efficacy and Safety of Potassium-Competitive Acid Blockers Versus Proton Pump Inhibitors as Helicobacter pylori Eradication Therapy: A Meta-Analysis of Randomized Clinical Trials.
Shah A; Usman O; Zahra T; Chaudhari SS; Mulaka GSR; Masood R; Batool S; Saleem F
Cureus; 2023 Nov; 15(11):e48465. PubMed ID: 38074044
[No Abstract] [Full Text] [Related]
73. Efficacy and safety of once-daily esomeprazole for the treatment of gastroesophageal reflux disease in neonatal patients.
Davidson G; Wenzl TG; Thomson M; Omari T; Barker P; Lundborg P; Illueca M
J Pediatr; 2013 Sep; 163(3):692-8.e1-2. PubMed ID: 23800403
[TBL] [Abstract][Full Text] [Related]
74. Cost-effectiveness of the RefluxStop device for management of refractory gastroesophageal reflux disease in Switzerland.
Harper S; Kartha M; Mealing S; Borbély YM; Zehetner J
J Med Econ; 2024; 27(1):805-815. PubMed ID: 38820006
[TBL] [Abstract][Full Text] [Related]
75. Gastroesophageal reflux disease: exaggerations, evidence and clinical practice.
Ferreira CT; Carvalho Ed; Sdepanian VL; Morais MB; Vieira MC; Silva LR
J Pediatr (Rio J); 2014; 90(2):105-18. PubMed ID: 24184302
[TBL] [Abstract][Full Text] [Related]
76. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials.
Caro JJ; Salas M; Ward A
Clin Ther; 2001 Jul; 23(7):998-1017. PubMed ID: 11519776
[TBL] [Abstract][Full Text] [Related]
77. Potassium-competitive acid blockers: rethinking acid suppression for gastroesophageal reflux disease and
Antequera CM; Orleck K; Jacob R; Kenneally A; Wright WL
Postgrad Med; 2024 Mar; 136(2):131-140. PubMed ID: 38385191
[TBL] [Abstract][Full Text] [Related]
78. The Effect of Dexlansoprazole on Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis.
Nunes GP; Silveira TC; Marciano JVS; Dos Reis-Prado AH; Ferrisse TM; Dos Anjos EB; Fernandes MH
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279248
[TBL] [Abstract][Full Text] [Related]
79. Meta-analysis of Proton Pump Inhibitors in the Treatment of Pharyngeal Reflux Disease.
Jin X; Zhou X; Fan Z; Qin Y; Zhan J
Comput Math Methods Med; 2022; 2022():9105814. PubMed ID: 35912160
[TBL] [Abstract][Full Text] [Related]
80. Efficacy and safety of hangeshashinto for treatment of GERD refractory to proton pump inhibitors : Usual dose proton pump inhibitors plus hangeshashinto versus double-dose proton pump inhibitors: randomized, multicenter open label exploratory study.
Takeuchi T; Hongo H; Kimura T; Kojima Y; Harada S; Ota K; Takeuchi N; Noguchi T; Inoue T; Murano M; Higuchi K
J Gastroenterol; 2019 Nov; 54(11):972-983. PubMed ID: 31037449
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
